Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features

Ribeiro, Hugo; Rodrigues, Inês; Napoleão, Leonardo; Lira, Luís; Marques, Denise Helena França; Veríssimo, Manuel Teixeira; Andrade, José; Dourado, Marı́lia

doi:10.1016/j.biopha.2022.112958

Cited by 51 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Selective COX-2 inhibitors can reduce the incidence of GI side effects but some are associated with excessive CV risk. 44 COX-1 affects the synthesis of thromboxane A2 (TXA2) in platelets, which is associated with pro-platelet aggregation action and arterial vasoconstriction. The synthesis of prostacyclin (PGI2) in endothelial cells may be affected by COX-1 and COX-2.…”

Section: Discussionmentioning

confidence: 99%

Imrecoxib: Advances in Pharmacology and Therapeutics

Wang,

Zhu,

et al. 2024

DDDT

View full text Add to dashboard Cite

Imrecoxib, a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID), was discovered via the balanced inhibition strategy of COX-1/COX-2. It is indicated for the relief of painful symptoms of osteoarthritis. There have been some pharmacological and therapeutic advances since the approval of imrecoxib in 2011. However, an update review in this aspect is not yet available. Relevant literature until January 2024 was identified by search of PubMed, Web of science, Embase and CNKI. From the perspective of efficacy, imrecoxib provides relief of osteoarthritis symptoms, and potential off-label use for treatment of idiopathic pulmonary fibrosis, perioperative pain, hand-foot syndrome, axial spondyloarthritis, COVID-19, cartilage injury, and malignancies such as lung and colon cancer. From a safety point of view, imrecoxib showed adverse effects common to NSAIDs; however, it has lower incidence of new-onset hypertension than other types of selective COX-2 inhibitors, less gastrointestinal toxicities than non-selective NSAIDs, weaker risk of drug interaction than celecoxib, and more suitable for elderly patients due to balanced inhibition of COX-1/COX-2. From a pharmacoeconomic perspective, imrecoxib is more cost-effective than celecoxib and diclofenac for osteoarthritis patients. With the deepening of the disease pathophysiology study of osteoarthritis, new therapeutic schemes and pharmacological mechanisms are constantly discovered. In the field of osteoarthritis treatment, mechanisms other than the analgesic and anti-inflammatory effects of COX-2 inhibitors are also being explored. Taken together, imrecoxib is a moderate selective COX-2 inhibitor with some advantages, and there would be more clinical applications and research opportunities in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Imrecoxib: Advances in Pharmacology and Therapeutics

Wang,

Zhu,

et al. 2024

DDDT

View full text Add to dashboard Cite

show abstract

“…[18,19] Oral nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce systemic inflammation but are limited by poor penetration into some tissues and multiple complications including bleeding in the gastrointestinal system. [20,21] Patients suffering from STIs often face the dilemma of ambiguous therapeutic options, with systemic complications and ineffective drug penetration associated with traditional treatment options represented by oral NSAIDs medications and topical application of creams, making it difficult to completely eradicate STIs. Physical therapy modalities in traditional medicine can modulate immune function, restore immune homeostasis, and treat STIs.…”

Section: Introductionmentioning

confidence: 99%

Photothermal Microneedle Hydrogel Patch for Refractory Soft Tissue Injuries through Thermosensitized Anti‐Inflammaging Modulation

Zhu,

Liu,

Zhang

et al. 2024

Small Structures

View full text Add to dashboard Cite

Soft tissue injuries (STIs) are the most common cause of extremity pain and motion dysfunction. Persistent inflammatory activation of immune cells characterized by senescence‐associated secretory phenotype (SASP) and mitochondrial stress are considered the primary causes of STIs, a pathological process also termed inflammaging. Meanwhile, scavenging excessive “cellular waste” in the inflammaging microenvironment and further activating tissue repair processes remain elusive. Herein, an anti‐inflammaging photothermal hydrogel microneedle patch for treating STIs is developed. Taurine‐loaded Prussian blue nanoparticles (Taurine@PB) are encapsulated in a methacrylate‐based hyaluronic acid hydrogel (HAMA) and further fabricated into taurine@PB@HAMA@microneedles (TPH@MN) patches. The acidic microenvironment of chronic inflammation and mild photothermal effects promote taurine release and anti‐inflammaging immunomodulation, inhibiting mitochondrial stress via the SIRT3‐NF‐κB axis to promote glycolytic metabolic microenvironment of neutrophils reprogramming toward oxidative phosphorylation metabolism. Furthermore, TPH@MN activates macrophage efferocytosis and initiates the process of tissue repair. In mouse models of chronic diabetic wounds and tibialis anterior (TA) muscle injury, TPH@MN inhibits SASP expression and promotes STIs healing through thermosensitized anti‐inflammaging immunomodulation. In summary, TPH@MN circumvents the side effects of systemic administration, providing new translatable options in the treatment modalities for patients suffering from STIs worldwide.

show abstract

“…Current analgesics, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDS), relieve pain symptoms by inhibiting neuronal activity. However, their effects are unsatisfactory, and these drugs have serious toxicity and dose-limiting side effects (4)(5)(6). Due to the complexity of the mechanisms associated with chronic pain, researchers' incomplete understanding of the mechanism reduces the therapeutic effect.…”

Section: Introductionmentioning

confidence: 99%

Inflammation and histone modification in chronic pain

Jiang

Li-xi²,

Tan³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Increasing evidence suggests that epigenetic mechanisms have great potential in the field of pain. The changes and roles of epigenetics of the spinal cord and dorsal root ganglia in the chronic pain process may provide broad insights for future pain management. Pro-inflammatory cytokines and chemokines released by microglia and astrocytes, as well as blood-derived macrophages, play critical roles in inducing and maintaining chronic pain, while histone modifications may play an important role in inflammatory metabolism. This review provides an overview of neuroinflammation and chronic pain, and we systematically discuss the regulation of neuroinflammation and histone modifications in the context of chronic pain. Specifically, we analyzed the role of epigenetics in alleviating or exacerbating chronic pain by modulating microglia, astrocytes, and the proinflammatory mediators they release. This review aimed to contribute to the discovery of new therapeutic targets for chronic pain.

show abstract

Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features

Cited by 51 publications

References 18 publications

Imrecoxib: Advances in Pharmacology and Therapeutics

Imrecoxib: Advances in Pharmacology and Therapeutics

Photothermal Microneedle Hydrogel Patch for Refractory Soft Tissue Injuries through Thermosensitized Anti‐Inflammaging Modulation

Inflammation and histone modification in chronic pain

Contact Info

Product

Resources

About